ZA200102268B - Methods and compositions for increasing intestinal absorption of fats. - Google Patents

Methods and compositions for increasing intestinal absorption of fats. Download PDF

Info

Publication number: ZA200102268B
Authority: ZA; South Africa
Prior art keywords: fatty acid; lysophosphatidylcholine; monoglyceride; agent; isolated complex
Prior art date: 1998-09-08

Application number

ZA200102268A

Other languages

English (en)

Inventor

David W Yesair

Original Assignee

Biomolecular Products Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-08

Filing date

1999-09-07

Publication date

2001-09-19

1999-09-07 Application filed by Biomolecular Products Inc filed Critical Biomolecular Products Inc

2001-09-19 Publication of ZA200102268B publication Critical patent/ZA200102268B/en

Links

239000000203 mixture Substances 0.000 title claims abstract description 50
238000000034 method Methods 0.000 title claims abstract description 24
239000003925 fat Substances 0.000 title description 19
230000031891 intestinal absorption Effects 0.000 title description 4
RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims abstract description 66
150000002632 lipids Chemical class 0.000 claims abstract description 35
210000000936 intestine Anatomy 0.000 claims abstract description 15
238000010521 absorption reaction Methods 0.000 claims abstract description 12
235000014113 dietary fatty acids Nutrition 0.000 claims description 72
229930195729 fatty acid Natural products 0.000 claims description 72
239000000194 fatty acid Substances 0.000 claims description 72
150000004665 fatty acids Chemical class 0.000 claims description 43
-1 diglycerides Chemical class 0.000 claims description 37
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 33
239000003795 chemical substances by application Substances 0.000 claims description 29
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 28
102000015439 Phospholipases Human genes 0.000 claims description 21
108010064785 Phospholipases Proteins 0.000 claims description 21
ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims description 20
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 18
229930006000 Sucrose Natural products 0.000 claims description 11
239000005720 sucrose Substances 0.000 claims description 11
229920000223 polyglycerol Polymers 0.000 claims description 10
235000012000 cholesterol Nutrition 0.000 claims description 8
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims description 7
150000001840 cholesterol esters Chemical class 0.000 claims description 6
150000001841 cholesterols Chemical class 0.000 claims description 6
150000003626 triacylglycerols Chemical class 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
210000002966 serum Anatomy 0.000 claims description 4
238000011282 treatment Methods 0.000 claims description 4
230000015556 catabolic process Effects 0.000 claims description 2
238000006731 degradation reaction Methods 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
102100037611 Lysophospholipase Human genes 0.000 abstract 1
108010058864 Phospholipases A2 Proteins 0.000 abstract 1
150000002500 ions Chemical class 0.000 description 10
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
229940088598 enzyme Drugs 0.000 description 8
239000002243 precursor Substances 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
239000011575 calcium Substances 0.000 description 7
150000003839 salts Chemical class 0.000 description 7
230000000694 effects Effects 0.000 description 6
230000000968 intestinal effect Effects 0.000 description 6
201000003883 Cystic fibrosis Diseases 0.000 description 5
239000002245 particle Substances 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
239000002253 acid Substances 0.000 description 4
125000002252 acyl group Chemical group 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
230000007062 hydrolysis Effects 0.000 description 4
238000006460 hydrolysis reaction Methods 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
206010025476 Malabsorption Diseases 0.000 description 3
208000004155 Malabsorption Syndromes Diseases 0.000 description 3
206010041969 Steatorrhoea Diseases 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
235000013367 dietary fats Nutrition 0.000 description 3
125000005313 fatty acid group Chemical group 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
239000007788 liquid Substances 0.000 description 3
229920000728 polyester Polymers 0.000 description 3
208000001162 steatorrhea Diseases 0.000 description 3
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
102000004882 Lipase Human genes 0.000 description 2
108090001060 Lipase Proteins 0.000 description 2
239000004367 Lipase Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical group 0.000 description 2
239000006172 buffering agent Substances 0.000 description 2
229910001424 calcium ion Inorganic materials 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000029087 digestion Effects 0.000 description 2
235000013305 food Nutrition 0.000 description 2
238000009472 formulation Methods 0.000 description 2
235000019421 lipase Nutrition 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
235000003441 saturated fatty acids Nutrition 0.000 description 2
150000004671 saturated fatty acids Chemical class 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000032258 transport Effects 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
208000003807 Graves Disease Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000019280 Pancreatic lipases Human genes 0.000 description 1
108050006759 Pancreatic lipases Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000001842 enterocyte Anatomy 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
230000036449 good health Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
235000018343 nutrient deficiency Nutrition 0.000 description 1
235000021231 nutrient uptake Nutrition 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
235000006180 nutrition needs Nutrition 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
229940116369 pancreatic lipase Drugs 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000000700 radioactive tracer Substances 0.000 description 1
239000000523 sample Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
235000021122 unsaturated fatty acids Nutrition 0.000 description 1
150000004670 unsaturated fatty acids Chemical class 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01004—Phospholipase A2 (3.1.1.4)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

ZA200102268A 1998-09-08 1999-09-07 Methods and compositions for increasing intestinal absorption of fats. ZA200102268B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US9943098P	1998-09-08	1998-09-08

Publications (1)

Publication Number	Publication Date
ZA200102268B true ZA200102268B (en)	2001-09-19

Family

ID=22274976

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200102268A ZA200102268B (en)	1998-09-08	1999-09-07	Methods and compositions for increasing intestinal absorption of fats.

Country Status (13)

Country	Link
US (1)	US6426069B1 (de)
EP (1)	EP1119360B1 (de)
JP (1)	JP4700193B2 (de)
CN (1)	CN1321089A (de)
AT (1)	ATE347371T1 (de)
AU (1)	AU771901B2 (de)
CA (1)	CA2343116C (de)
DE (1)	DE69934325T2 (de)
IL (2)	IL141801A0 (de)
NO (1)	NO20011173L (de)
NZ (1)	NZ510536A (de)
WO (1)	WO2000013689A1 (de)
ZA (1)	ZA200102268B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2788500C (en) *	2001-10-11	2017-08-01	Biomolecular Products, Inc.	Modifications of solid 3-sn-phosphoglycerides
EP1350435B1 (de)	2002-04-05	2010-12-22	Societe Des Produits Nestle S.A.	Zusammensetzungen und Verfahren zur Verbesserung von Lipidassimilation in Haustieren
DE10217555A1 (de) *	2002-04-19	2004-02-19	Degussa Bioactives Deutschland Gmbh	Physiologisch verträgliche, Phospholipid-haltige, stabile und harte Matrix
PT1594544T (pt) *	2003-01-31	2016-07-14	Los Angeles Childrens Hospital	Composições orais de fenretinida tendo biodisponibilidade aumentada e métodos de utilização das mesmas
US7758884B2 (en) *	2005-01-28	2010-07-20	Kemin Industries, Inc.	Formulation for increasing the deposition of dietary carotenoids in eggs
EP1688049A1 (de) *	2005-02-03	2006-08-09	findusFit Sportdiätetika GmbH	Diätetisches Lebensmittel
FR2918846B1 (fr) *	2007-07-20	2013-07-26	Isl Innovation Sante Lipides	Composition alimentaire pour ameliorer la digestibilite des lipides alimentaires
JP5768294B2 (ja) *	2010-10-22	2015-08-26	学校法人福岡大学	胃上皮性腫瘍（腺腫・胃癌）の診断に有用な白色不透明物質を応用した診断能改善用組成物
CA2817957C (en) *	2010-11-15	2016-05-10	Texas Tech University	Substance for increasing the production of a specific acyl-chain dihydroceramide(s) for improving the effectiveness of cancer treatments
BR112021002490A2 (pt) *	2018-09-21	2021-10-19	Société des Produits Nestlé S.A.	Composições e métodos para o tratamento de insuficiência pancreática exócrina (ipe)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4874795A (en) *	1985-04-02	1989-10-17	Yesair David W	Composition for delivery of orally administered drugs and other substances
US4849132A (en)	1986-05-16	1989-07-18	Asahi Denka Kogyo Kabushiki Kaisha	Surfactant composition having improved functions
US5571517A (en)	1990-08-13	1996-11-05	Yesair; David W.	Mixed lipid-bicarbonate colloidal particles for delivering drugs or calories
AU666293B2 (en) *	1990-08-13	1996-02-08	David W. Yesair	Mixed lipid-bicarbonate colloidal particles for delivering drugs or calories
US5302400A (en) *	1992-06-22	1994-04-12	Digestive Care Inc.	Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids
JPH08143469A (ja) *	1994-11-14	1996-06-04	Amano Pharmaceut Co Ltd	膵外分泌機能不全症治療剤
CA2222161C (en) *	1995-06-06	2002-02-05	Biomolecular Products, Inc.	Mixed lipid-bicarbonate colloidal particles for delivering drugs or calories
US5716814A (en)	1996-02-02	1998-02-10	Biomolecular Products, Inc.	Methods for making lysophosphatidylcholine
US20030175277A1 (en)	1996-09-11	2003-09-18	Elizabeth Shanahan-Prendergast	Therapeutic formulations containing venom or venom anti-serum either alone or in combination for the therapeutic prophylaxis and therapy of neoplasms

1999
- 1999-09-07 DE DE69934325T patent/DE69934325T2/de not_active Expired - Lifetime
- 1999-09-07 AU AU57052/99A patent/AU771901B2/en not_active Ceased
- 1999-09-07 AT AT99944090T patent/ATE347371T1/de not_active IP Right Cessation
- 1999-09-07 NZ NZ510536A patent/NZ510536A/en not_active IP Right Cessation
- 1999-09-07 EP EP99944090A patent/EP1119360B1/de not_active Expired - Lifetime
- 1999-09-07 JP JP2000568497A patent/JP4700193B2/ja not_active Expired - Fee Related
- 1999-09-07 CA CA002343116A patent/CA2343116C/en not_active Expired - Fee Related
- 1999-09-07 WO PCT/US1999/020427 patent/WO2000013689A1/en active IP Right Grant
- 1999-09-07 ZA ZA200102268A patent/ZA200102268B/en unknown
- 1999-09-07 US US09/786,695 patent/US6426069B1/en not_active Expired - Lifetime
- 1999-09-07 IL IL14180199A patent/IL141801A0/xx active IP Right Grant
- 1999-09-07 CN CN99811075A patent/CN1321089A/zh active Pending
2001
- 2001-03-04 IL IL141801A patent/IL141801A/en not_active IP Right Cessation
- 2001-03-07 NO NO20011173A patent/NO20011173L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2343116A1 (en)	2000-03-16
DE69934325D1 (de)	2007-01-18
NZ510536A (en)	2003-07-25
EP1119360A4 (de)	2003-06-04
JP2002524417A (ja)	2002-08-06
US6426069B1 (en)	2002-07-30
EP1119360B1 (de)	2006-12-06
IL141801A0 (en)	2002-03-10
CN1321089A (zh)	2001-11-07
JP4700193B2 (ja)	2011-06-15
DE69934325T2 (de)	2007-07-05
CA2343116C (en)	2008-11-18
AU5705299A (en)	2000-03-27
AU771901B2 (en)	2004-04-08
ATE347371T1 (de)	2006-12-15
NO20011173D0 (no)	2001-03-07
EP1119360A1 (de)	2001-08-01
WO2000013689A1 (en)	2000-03-16
IL141801A (en)	2009-02-11
NO20011173L (no)	2001-05-08

Publication	Publication Date	Title
US7807718B2 (en)	2010-10-05	Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
AU2003267818B2 (en)	2009-12-17	Composition containing arachidonic acid alone or in combination with docosahexaenoic acid for enhancing cognitive abilities
ES2369074T3 (es)	2011-11-25	Composiciones que tienen efectos preventivos o mejoradores de síntomas o enfermedades provocados por una hipofunción cerebral.
US20070042008A1 (en)	2007-02-22	Compositions containing phosphatidylcholine and essential fatty acids
JP2004531568A (ja)	2004-10-14	補酵素ｑおよびエイコサペンタエン酸（ｅｐａ）
JPH08193028A (ja)	1996-07-30	ヘリコバクターの阻害
WO2008149177A2 (en)	2008-12-11	Marine lipid compositions and uses thereof
US6426069B1 (en)	2002-07-30	Method and compositions for increasing intestinal absorption of fats
Hayes et al.	1994	Review of triacylglycerol digestion, absorption, and metabolism with respect to SALATRIM triacylglycerols
JP3467794B2 (ja)	2003-11-17	学習能向上剤
US20080058286A1 (en)	2008-03-06	Novel applications of omega-3 rich phospholipids
Nishimukai et al.	2003	Enteral administration of soyabean lecithin enhanced lymphatic absorption of triacylglycerol in rats
WO2001049282A2 (en)	2001-07-12	Therapeutic preparations of highly unsaturated fatty acids
WO2000009138A1 (fr)	2000-02-24	Compositions a finalite nutritionnelle pour prevenir ou traiter l'hyperlipoproteinemie
US7842679B2 (en)	2010-11-30	Phospholipid derivatives of DHA and methods for treating respiratory failure using the same
Chen et al.	2010	Docosahexaenoic acid-containing phospholipids and triglycerides based nutritional supplements
Tamargo et al.	2016	Pharmacokinetics and safety profile of omega-3 polyunsaturated fatty acids
KR100850646B1 (ko)	2008-08-07	인지질 조성물 제조방법
US20030032672A1 (en)	2003-02-13	Method for preparing a conjugated linoleic acid-containing structured lipid and use of the same
Staggers	1984	Lipid digestion and absorption in the suckling rat.
JPS62111926A (ja)	1987-05-22	コリン作働性神経系活性化剤
Kim et al.	2008	Dietary structured lipids and phytosteryl esters: blood lipids and cardiovascular status in spontaneously hypertensive rats
JPWO2007132888A1 (ja)	2009-09-24	平滑筋収縮抑制剤
British Nutrition Foundation	1992	Digestion of Lipids to Unsaturated Fatty Acids